Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Conditions
Malignant Pleural Mesothelioma
Conditions: official terms
Mesothelioma
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Retrospective
Overall Status
Recruiting
Summary
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on clinical outcome.

Sample size: around 150 patients based on the availability of tumor size
Detailed Description
Vinorelbine has recently become an alternative option for palliation in selected pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM). However, nowadays there are no definitive data about vinorelbine predictors of response in MPM patients. The identification of molecular predictors of effective therapy is important for maximizing therapeutic efficacy and minimizing useless treatment in cancer patients.

In oncology a pharmacogenetic approach to customize the chemotherapy treatment according to individual as well as tumour genetic characteristics represents a modern and intriguing challenge. Recent studies have suggested that the expression levels of class III β-tubulin (TUBB3) or BRCA1, are related to a survival benefit from vinorelbine chemotherapy among patients with advanced solid malignancies, especially non-small cell lung cancer. There are no data about the predictive factors to vinorelbine in MPM patients. The identification of molecular predictors of effective therapy may allow in the future the development of better therapies.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- MPM patients treated with vinorelbine in the ≥ second line setting will be retrospectively analyzed

- Patients will be selected based on the availability of tumor tissue

Exclusion Criteria:

- NA
Location
Istituto Clinico Humanitas
Rozzano, Milan, Italy
Status: Recruiting
Contact: Armando Santoro, MD - +39 02 8224 4080 - armando.santoro@cancercenter.humanitas.it
Start Date
November 2012
Completion Date
September 2015
Sponsors
Armando Santoro, MD
Source
Istituto Clinico Humanitas
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page